Chen Ru, Hu Bing, Jiang Ming, Deng Wen, Zheng Ping, Fu Bin
Department of Urology, the First Affiliated Hospital of Nanchang University, Nanchang City, Jiangxi Province, People's Republic of China.
Department of Urology, The First Hospital of Putian City, Putian, Fujian, People's Republic of China.
Int J Gen Med. 2022 Jun 7;15:5465-5485. doi: 10.2147/IJGM.S368573. eCollection 2022.
The minichromosome maintenance (MCM) complex (MCM2, MCM3, MCM4, MCM5, MCM6, and MCM7), which regulates DNA replication and cell cycle progression, is essential for the development and progression of multiple tumors, but their role in bladder cancer development remains unclear. In the present study, the biological role and clinical significance of the MCM complex in bladder cancer were systematically elucidated.
We analyzed DNA mutations, mRNA expression and protein levels, protein-protein interaction (PPI) networks, functional enrichment, prognostic value of MCM2/3/4/5/6/7 in bladder urothelial carcinoma (BLC) and the connections between the immune cell infiltration and the overall survival of BLC patients with the MCM expression levels using Oncomine, Gene Expression Profiling Interactive Analysis (GEPIA), the Cancer Genome Atlas database (TCGA), Human Protein Atlas, UALCAN, STRING, cBioPortal, TIMER and GSCALite databases.
The outcomes showed that the mRNA expression level of each member of the MCM complex was significantly correlated with histologic grade and tumor histology in BLC patients. Moreover, survival analysis showed that MCM/2/3/4/5/6/7 mRNA expressions were significantly associated with prognosis in patients with bladder cancer. Moreover, we experimentally validated the overexpression of the MCM2-7 complex in the BLC. Based on functional enrichment and PPI network analysis, the MCM complex might promote the progression of bladder cancer by activating DNA replication and accelerating cell cycle progression. In addition, MCM2/3/4/5/6/7 genes were also significantly associated with tumor immune cells infiltration and the drug sensitivity in BLC.
Our study suggests that the MCM complex especially MCM2/4/6/7 might be potential molecular therapeutic targets for BLC treatment and might be useful biomarkers for diagnosis and prognosis.
微小染色体维持(MCM)复合体(MCM2、MCM3、MCM4、MCM5、MCM6和MCM7)可调节DNA复制和细胞周期进程,对多种肿瘤的发生和发展至关重要,但其在膀胱癌发生中的作用仍不明确。在本研究中,系统阐明了MCM复合体在膀胱癌中的生物学作用和临床意义。
我们使用Oncomine、基因表达谱交互式分析(GEPIA)、癌症基因组图谱数据库(TCGA)、人类蛋白质图谱、UALCAN、STRING、cBioPortal、TIMER和GSCALite数据库分析了MCM2/3/4/5/6/7在膀胱尿路上皮癌(BLC)中的DNA突变、mRNA表达和蛋白质水平、蛋白质-蛋白质相互作用(PPI)网络、功能富集、预后价值以及免疫细胞浸润与MCM表达水平对BLC患者总生存的关联。
结果显示,MCM复合体各成员的mRNA表达水平与BLC患者的组织学分级和肿瘤组织学显著相关。此外,生存分析表明,MCM/2/3/4/5/6/7 mRNA表达与膀胱癌患者的预后显著相关。此外,我们通过实验验证了MCM2 - 7复合体在BLC中的过表达。基于功能富集和PPI网络分析,MCM复合体可能通过激活DNA复制和加速细胞周期进程促进膀胱癌的进展。此外,MCM2/3/4/5/6/7基因也与BLC中的肿瘤免疫细胞浸润和药物敏感性显著相关。
我们的研究表明,MCM复合体尤其是MCM2/4/6/7可能是BLC治疗的潜在分子治疗靶点,可能是诊断和预后的有用生物标志物。